Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Shares Outstanding (Diluted Average) (2020 - 2025)

Puma Biotechnology (PBYI) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $50.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 3.16% year-over-year to $50.7 million, compared with a TTM value of $50.7 million through Dec 2025, up 3.16%, and an annual FY2025 reading of $50.7 million, up 3.16% over the prior year.
  • Shares Outstanding (Diluted Average) was $50.7 million for Q4 2025 at Puma Biotechnology, up from $49.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $50.7 million in Q4 2025 and bottomed at $40.6 million in Q4 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $46.6 million, with a median of $47.6 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) increased 2.69% in 2021, then grew 10.56% in 2022.
  • Year by year, Shares Outstanding (Diluted Average) stood at $40.6 million in 2021, then rose by 10.56% to $44.9 million in 2022, then rose by 5.83% to $47.6 million in 2023, then grew by 3.26% to $49.1 million in 2024, then grew by 3.16% to $50.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for PBYI at $50.7 million in Q4 2025, $49.1 million in Q4 2024, and $47.6 million in Q4 2023.